~~<i id='8F6C20272D'><strike id='8F6C20272D'><tt id='8F6C20272D'><pre id='8F6C20272D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

focus

author：Wikipedia 2025-09-28 19:25:05 - browse：8

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： FDA investigates CAR

explore

hotspot

leisure time

focus

knowledge

focus

Paxlovid,Pfizer'spilltotreatCovid-19PfizerPaxlovid,Pfizer’spilltotreatCovid-19,retainedits89%efficac

WSS

Brain 'hot spot' may explain why African Americans feel greater pain

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Make 'food is medicine' a key part of White House nutrition meeting

When is a doctor not a doctor? Try when patients address women doctors

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Cigna, Humana reportedly in talks to merge

leisure time

focus

explore

In age of alternative facts, a scholarly course on calling out crap

Flagship Pioneering launches a new biotech in two countries

Tori Bowie and the unacceptable rates of Black maternal death

UnitedHealth’s Optum accused of antitrust violations in California

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Walensky prepares to leave CDC — and Congress — behind

Make 'food is medicine' a key part of White House nutrition meeting

BioMarin wins approval for gene therapy to treat hemophilia A

Why is France rioting? What to know about the fatal police shooting of Nahel M

hotspot

Did the public have the right to know Arthur Ashe had AIDS?

With clinical trial data readouts, here's how to spot spin

BIO selects John Crowley as new CEO

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

UnitedHealth’s Optum accused of antitrust violations in California

New case study details death in closely watched Alzhiemer's trial

leisure time

focus

knowledge

focus